TECHSTARS
30.6.2021 13:02:08 CEST | Business Wire | Press release
Techstars, the worldwide network that helps entrepreneurs succeed, today announced an exciting new accelerator program. The Launchpool Web3 Techstars Accelerator focuses on working with entrepreneurs to build blockchain technology and tokenisation protocols to drive towards the decentralised future of finance.
The program runs in partnership with Alphabit Fund, the first regulated cryptocurrency and digital asset investment fund, and Launchpool, a regulatory compliant investment platform that offers private seed guaranteed investment opportunities to 35,000 members in its community.
Techstars maintains notable experience and expertise in the blockchain space, with a number of strong blockchain companies in the Techstars portfolio including Chainalysis , recently valued at $2 billion, Arweave , TradingView , and more.
“Blockchain technology has the potential to shift the control of monetary value and information and disrupt global business processes, as the Internet did in the early 2000s,” said Techstars General Manager Gagan Bhatia. “Working with Alphabit and the Launchpool community to support leading companies in this space is an incredible opportunity and an investment in the decentralized economy of the future.”
Located in London, the Launchpool Web3 Techstars Accelerator will work with ten startups each year over an intensive, three-month acceleration period. They will receive funding, hands-on mentorship, exposure to a minimum viable community, access to curated workshops and resources, and join the Techstars global network for life. Applications open from September 13 to December 1, 2021 and the first year of the accelerator will operate from March to June 2022.
“Alphabit is thrilled Techstars is partnering with Launchpool and us to bring the first Techstars accelerator to the crypto world. As firm believers in a multichain future, and being passionate about mainstream adoption, this first of its kind accelerator is proud to be chain agnostic,” said Shane McQuillan, VP Strategy of Alphabit.
Learn about Launchpool Web3 Techstars Accelerator here . For partnership opportunities with Techstars, contact Will Robinson or visit techstars.com/corporations .
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas — entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,500 companies with a combined market cap of more than $200B. www.techstars.com
About Alphabit
One of the first regulated crypto asset funds, Alphabit has forged a reputation for investing in companies at the cutting edge of the blockchain revolution. Alphabit believes, supports, and invests in the decentralised economy of the future, with a generous portfolio of startups, protocols, and DeFi solutions that address an alternative to traditional financial systems. www.alphabit.fund
About Launchpool
Launchpool is a regulatory compliant initiative started in 2020 by Alphabit Digital Currency Fund with the aim of providing fair guaranteed access to early stages of project raises to the retail community. With the ethos of ‘Egalitarian Investment’, Launchpool’s global community of 35,000 investors believe in the idea of being your own VC, while supporting the startups ecosystem with a minimum viable community, resources, access to funding opportunities, and enabling partnerships across the blockchain ecosystem. www.launchpool.xyz
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005495/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom